Niki BioSolutions, Inc. · NASDAQ:NIKI
Niki BioSolutions — Aptorum Group — IPO Roadshow (October 2018)
30 slides from Niki BioSolutions's IPO roadshow presentation, Oct 10, 2018
Slide 1: Corporate Presentation – Nasdaq Global Market IPO Q4 2018
CONFIDENTI AL OUR MISSION IS TO FACILITATE LIFE SCIENCE INNOVATIONS TO SERVE UNMET MEDICAL NEEDS Corporate Presentation Underwritten By: NASDAQ GLOBAL MARKET IPO Q4 2018
Slide 2: Issuer Free Writing Prospectus
2 CONFIDENTI AL FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Registration Statement No. 333 - 227198 The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates (fi
Slide 3: Disclaimer
3 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited Aptorum Group Limited has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates (file no. 333 - 227198). Before you invest, you should read the prospectus in that registration s
Slide 4: Offering Summary
4 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited ISSUER Aptorum Group Limited SECURITY Class A Ordinary Shares TICKER / EXCHANGE APM on Nasdaq Global Market SHARES OUTSTANDING PRIOR TO COMPLETION OF OFFERING 5,426,381 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares SHARES OFFERE
Slide 5: Investment Highlights
5 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited Diversified portfolio (MRSA, Influenza, Endometriosis, etc.) Management team coupled with medical talents and prominent scientific advisor y board Board of directors with diverse background and accomplishments in finance and in healthcare indust
Slide 6: Business Model
6 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited BUSINESS MODEL CRE A T E Sc r eening Proces s Basic Research Idea IND - Enabling Phase 1 Phase 3 Phase 2 Clinical Trials * Decisions on whether to continue development and commercialization of our early - stage projects would heavily depend on t
Slide 7: Executive Management
CONFIDENTI AL MR. IAN HUEN Founder, Chief Executive Officer and Executive Director MR. DARREN LUI President, Chief Business Officer and Executive Director DR. CLARK CHENG Chief Medical Officer and Executive Director • Over 15 years in global asse t management • US healthcare equity research analyst
Slide 8: Board of Directors and Advisors
CONFIDENTI AL PROFESSOR DOUGLAS ARNER Independent Non - Executive Director Kerry Holdings Professor in Law, HKU DR. JUSTIN WU Independent Non - Executive Director Chief Operating Officer of CUHK Medical Centre DR. MIRKO SCHERER Independent Non - Executive Director CEO of TVM Capital China MR. CHARLE
Slide 9: Project Portfolio: Drug and Device Candidates
CONFIDENTI AL PROJECT PORTFOLIO DRUG AND DEVICE CANDIDATES PROJECTS CANDIDATE / MODALITY INDICATION DEVELOPMENT STAGE Target Identification & Selection Lead Discove r y Lead Optimization IND - Enabling Phase 1 Phase 2 Phase 3 VIDENS’ SERIES VLS - 1 Curcumin - MNP (Medical Imaging Agent for MRI Diagn
Slide 10: Project Portfolio
CONFIDENTI AL PROJECT PORTFOLIO PROJECTS CANDIDATE / MODALITY INDICATION DEVELOPMENT STAGE Target Identification & Selection Lead Discove r y Lead Optimization IND - Enabling Phase 1 Phase 2 Phase 3 NATIVUS’ SERIES NLS - 1 Small molecule Treatment of Endometriosis NLS - 2 An extract from Chinese yam
Slide 11: Overview of Our Lead Projects
CONFIDENTI AL OVERVIEW OF OUR LEAD PROJECTS ALS - 1 INFLUENZA A ALS - 4 STAPHYLOCOCCUS INCLUDING METHICILLIN - RESISTANT S. AUREUS (MRSA) NLS - 1 ENDOMETRIOSIS Population affected: Annual epidemics estimated to result in ~ 3 - 5 million cases of serious influenza infections, causing about 290 , 000
Slide 12: Lead Project ALS-1: Influenza A
CONFIDENTI AL LEAD PROJECT - ALS - 1 1 2 © Copyright 2018 Aptorum Group Limited For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. A SMALL MOLECULE FOR THE TREATMENT OF VIRAL INFECTIONS CAUSED BY INFLUENZA VIRUS A CHARACTERISTICS • Smal
Slide 13: ALS-1 In Vitro Efficacy Data
CONFIDENTI AL This figure shows the concentration dependence of ALS - 1 in reducing the plaque - forming unit (pfu, a measure of number of infectious virus particulates, which represents the in vitro efficacy of the drug) of human H 1 N 1 , H 3 N 2 and H 5 N 1 influenza viruses . Th e IC 50 (the con
Slide 14: Current Treatment Options for Influenza A
CONFIDENTI AL CURRENT TREATMENT OPTIONS for Viral Infections Caused by Influenza A COMPANY PRODUCT (GENERIC NAME) PRODUCT (BRAND NAME) FORMULATION FDA APPROVAL (YEAR) AVAILABILITY OF GENERIC VERSIONS GlaxoSmithKline (GSK) Zanamivir Relenza Powder 1999 N Roche Oseltamivir Tamiflu Capsule, for Suspens
Slide 15: Lead Project ALS-4: Staphylococcus aureus including MRSA
CONFIDENTI AL LEAD PROJECT - ALS - 4 1 5 © Copyright 2018 Aptorum Group Limited For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. A SMALL MOLECULE FOR THE TREATMENT OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS INCLUDIN G MRSA CHARACTE
Slide 16: ALS-4 Inhibition of Pigment Formation
CONFIDENTI AL A Small Molecule for the Treatment of Infections Caused by Staphylococcus Aureus Including MRSA LEAD PROJECT - ALS - 4 A SMALL MOLECULE FOR THE TREATMENT OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS INCLUDING MRSA ALS - 4 has been developed to inhibit the formation of the golden pigme
Slide 17: Current Treatment Options for MRSA
1 7 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited CURRENT TREATMENT OPTIONS PRODUCT (GENERIC NAME) Cefazolin Dicloxacillin Cefuroxime Vancomycin Cephalexin Clindamycin Nafcillin Rifampin Oxacillin Telavancin FOR MRSA • Non - antibiotic approach designed to reduce the likelihood for drug resis
Slide 18: Lead Project NLS-1: Endometriosis
CONFIDENTI AL LEAD PROJECT - NLS - 1 18 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2018 Aptorum Group Limited PRO - EGCG, A DERIVATIVE OF EPIGALLOCATECHIN - 3 - GALLATE FOR THE TREATMENT OF ENDOMETRIOSIS CHARACTERIST
Slide 19: NLS-1 Efficacy in Mouse Endometriosis Model
CONFIDENTI AL LEAD PROJECT - NLS - 1 Compared with Vitamin E, EGCG and the control without any treatment, we believe NLS - 1 offers superior efficacy in terms of reduction in the size and weight of lesions in a mouse endometriosis model . Compared with Vitamin E, EGCG and the control without any tre
Slide 20: Current Treatment Options for Endometriosis
CONFIDENTI AL CURRENT TREATMENT OPTIONS 20 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2018 Aptorum Group Limited FOR ENDOMETRIOSIS CURRENT HORMONAL TREATMENTS PRODUCT (GENERIC NAME) GnRH agonist Leuprorelin Goserelin
Slide 21: Other Projects Under Development
CONFIDENTI AL OTHER PROJECTS UNDER DEVELOPMENT A L S - 2 A L S - 3 V L S - 1 V L S - 3 V L S - 4 • A small molecule targeting bacterial virulence for the treatment of bacterial infections caused by Staphylococcus aureus including MRSA, by suppressing the expression of multiple virulence factors simu
Slide 22: Other Projects Under Development (continued)
CONFIDENTI AL V L S - 2 N L S - 2 N L S - 3 SP L S - 1 • We believe VLS - 2 is a small drug molecule that appears to activate autophagy without inhibiting mTOR function, an endogenous cellular mechanism for clearing multiple pathological protein aggregates including tau, which are responsible for th
Slide 23: Device Under Development
CONFIDENTI AL DEVICE UNDER DEVELOPMENT • Robotic catheter platform for MRI - guided cardiovascular intervention for the treatment of arrhythmia; • The platform consists of a magnetic resonance imaging (“MRI - guided”) robotic electrophysiology (“EP”) catheter system, an MR - based positional trackin
Slide 24: Other Non-Therapeutic Projects
2 4 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited OTHER NON - THERAPEUTIC PROJECTS OTHER KEY PROJECTS ALS - DDC Drug Discovery Center + Chemical Library Drug discovery by identification and screening of drug molecules for various indications Setting Up AML Clinic Clinic - Talem Medical Medica
Slide 25: IP Around Lead Programs
2 5 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited IP AROUND LEAD PROGRAMS PROJECT COMPANY / PROJECT NAME LICENSOR(S) LICENSEE LICENSED / IP RIGHTS PATENT EXPIRATION DATES Acticule / ALS - 1 Versitech Limited Acticule Life Sciences Limited Exclusive licensee: 1 U.S. patent (US9212177), 1 Europ
Slide 26: Financial Overview
2 6 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited FINANCIAL OVERVIEW (US$) ROUNDED TO THE NEAREST THOUSAND Cash and restricted cash, and marketable securities US$18,698,000 (as of 12/31/2017) US$25,022,000 (as of 6/30/2018) Intangible assets, net US$1,473,000 (as of 12/31/2017) US$1,452,000 (
Slide 27: Use of Net Proceeds
2 7 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited USE OF NET PROCEEDS (Minimum offering amount of US$10) (in millions) USE OF NET PROCEEDS (Maximum offering amount of US$30) (in millions) Fund preclinical and clinical development: Development through Phase 1 of our Lead Projects i Development
Slide 28: Appendix
APPENDI X
Slide 29: Selected Income Statement Summary and Balance Sheet Items
2 9 CONFIDENTI AL © Copyright 2018 Aptorum Group Limited SELECTED INCOME STATEMENT SUMMARY (US GAAP) Ten months ended December 31, 2017 Six months ended June 30, 2018 US $ US $ Healthcare services income - 26,662 Costs of healthcare services - 22, 7 49 Research and development expenses 2,560,323 1,3
Slide 30: Aptorum Group Limited Contacts
APTORUM GROUP LIMITED investor.relations@aptorumgroup.co m T +852 2117 6611 F +852 2850 7286 DAN MCCLORY Managing Director & Head of Capital Equity Markets dan@boustead1828.com +1 (949) 233 - 7869 JOE LAI Managing Director Head of HK Healthcare IBD (HK) joelai@chinarenaissance.com +(852) 2287 - 1695